A multicenter, open-label, prospective study of durvalumab, etoposide, and carboplatin for unresectable small cell lung cancer with mild idiopathic interstitial pneumonia - DREAM study A multicenter, open-label, prospective study of durvalumab, etoposide, and carboplatin for unresecta ...
Small cell lung cancer
Patients will receive etoposide (<75 years old: 100mg/m2; >=75 years old: 80mg/m2; intravenously on day 1-3), carboplatin (area under the curve 5 mg/mL intravenously on day 1), and durvalumab (1500mg/body intravenously on day1) every three weeks for four cycles. Thereafter, patients will continue to receive durvalumab monotherapy (1500mg/body intravenously on day 1 every three weeks), until relapse, or unacceptable toxicity. Patients will receive etoposide(<75 years old: 100mg/m2; >=75 years old: 80mg/m2; intravenously on d ...